The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth

Michael D. Arensman, Donatello Telesca, Anna R. Lay, Kathleen M. Kershaw, Nanping Wu, Timothy R. Donahue, and David W. Dawson

The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer due in part to a lack of highly robust cytotoxic or molecular-based therapies. Recent studies investigating ligand-mediated Wnt/β-catenin signaling have highlighted its importance in pancreatic cancer initiation and progression, as well as its potential as a therapeutic target in PDAC. The small-molecule ICG-001 binds cAMP-responsive element binding (CREB)-binding protein (CBP) to disrupt its interaction with β-catenin and inhibit CBP function as a coactivator of Wnt/β-catenin-mediated transcription. Given its ability to inhibit Wnt/β-catenin-mediated transcription in vitro and in vivo, as well as its efficacy in preclinical models of colorectal cancer and other Wnt-driven diseases, we examined ICG-001 and its potential role as a therapeutic in PDAC. ICG-001 alone significantly inhibited anchorage-dependent and -independent growth of multiple PDAC lines, and augmented in vitro growth inhibition when used in combination with gemcitabine. ICG-001 had only variable modest effects on PDAC apoptosis and instead mediated PDAC growth inhibition primarily through robust induction of G1 cell-cycle arrest. These effects, however, seemed decoupled from its inhibition of Wnt/β-catenin-mediated transcription. DNA microarrays performed on PDAC cells in the context of ICG-001 treatment revealed ICG-001 altered the expression of several genes with well-established roles in DNA replication and cell-cycle progression, including direct actions on SKP2 and CDKN1A. ICG-001 also significantly prolonged survival in an in vivo orthotopic xenograft model of PDAC, indicating ICG-001 or derived compounds that disrupt CBP activity are potentially useful small-molecule therapeutics for pancreatic cancer.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest of cancers, with an overall 5-year survival rate of approximately 6% (1). PDAC is difficult to treat because it frequently presents at an advanced, nonoperative stage and is highly resistant to cytotoxic or targeted molecular therapy (2). Although our understanding of the molecular and cellular basis of PDAC continues to expand, present therapeutic options remain limited and offer only modest survival benefits for most patients.
(5, 14, 15). ICG-001 was identified in a screen of small molecules that inhibited Wnt/β-catenin transcriptional activity in a colorectal cancer cell line (16). ICG-001 selectively blocks the interaction of β-catenin with its transcriptional coactivator cAMP-responsive element binding (CREB)-binding protein (CBP) without disrupting β-catenin interaction with highly homologous p300. One significant effect ascribed to ICG-001 and its disruption of Wnt/β-catenin transcription is decreased expression of the apoptosis inhibitor BIRC5 (aka survivin protein), which leads to activation of caspase-3/7-mediated apoptosis (16–19). ICG-001 was first shown to slow colorectal cancer xenograft growth and intestinal polyp formation in the Apcmin mouse model (16) and has been subsequently shown to have in vivo efficacy in other Wnt-driven disease models, including rodent models of pulmonary fibrosis (20), renal interstitial fibrosis (21), acute lymphoblastic leukemia (22), chronic myocardial infarction (23), dermal fibrosis (24), and salivary tumorigenesis (25). The ICG-001–derived compound PRI-724 is now under investigation as a Wnt inhibitor in early-phase clinical trials for advanced solid tumors (NCT01302405) and myeloid malignancies (NCT01606579; ref. 26).

Given the importance of Wnt signaling in pancreatic carcinogenesis, we have now explored therapeutic potential and mechanism of action of ICG-001 in PDAC. ICG-001 significantly inhibited in vitro and in vivo PDAC growth by inducing G1 cell-cycle arrest through effects that were largely decoupled from its activity as a Wnt inhibitor. Instead, ICG-001 seemed to more broadly affect CBP function as a cotranscriptional activator, directly and indirectly perturbing the expression of numerous genes with key roles in cell-cycle progression.

Materials and Methods

Cell lines and reagents

All cell lines were cultured as previously described (7). AsPC-1, MiaPaCa-2, and PANC-1 were obtained in 2005 from the ATCC (Rockville, MD). L3.6pl was obtained in 2010 from Hong Wu (UCLA). The cell lines have not been subsequently authenticated since receipt. ICG-001 was purchased from Selleck Chem and gemcitabine was kindly provided by Timothy Donahue (UCLA). Wnt3a and L-cell conditioned media were prepared as previously described (7).

Cell growth, proliferation, and apoptosis assays

MTT cell viability assays (ATCC) were carried out per the manufacturer’s instructions at initial plating of 5,000 (AsPC-1 and L3.6pl) or 3,000 (MiaPaCa-2 and PANC-1) cells per well in 96-well plates. Soft agar assays to verify knockdown were performed using lentiviral constructs containing β-catenin–activated promoter driving Renilla expression.

Gene knockdown

Lipotectamine 2000 was used per the manufacturer’s instructions to transfect AsPC-1 cells with 20 nmol/L control siRNA (#12935-200) or CTNNB1 #4390824 siRNA (all purchased from Life Technologies). Western blot analyses to verify knockdown were performed using β-catenin (Sigma; C2206) and tubulin (Santa Cruz; sc-5546) antibodies.

Real-time PCR

RNA extraction, cDNA synthesis, and SYBR Green–based qPCR were performed as previously described (7) using primers listed in Supplementary Table S1.
Western blot analyses and immunoprecipitation

Western blot analyses were performed as previously described (7) using antibodies specific for β-catenin (Sigma; C2206), PARP [Cell Signaling Technology (CST); 9542], cleaved caspase-3 (CST; 9664), cleaved caspase-7 (CST; 9491), SKP2 (CST; 2652), MYC (Santa Cruz; sc-40), p21 (CST; 2947), or tubulin (Santa Cruz; sc-5546). CBP coimmunoprecipitations were performed on nuclear extracts as previously described (30) with anti-CBP (Santa Cruz; sc-369) or control isotype-matched IgG (Abcam; ab46540) antibodies.

Chromatin immunoprecipitation

AsPC-1 cells (70% confluency) were cross-linked with 1% formalin. Chromatin immunoprecipitation (ChIP) was performed using the Pierce Agarose ChIP Kit (Thermo Scientific) on chromatin digested with 2U micrococcal nuclease. Digested chromatin extracts were precleared with 20 μg agosear beads and incubated overnight with beads prebound with either 5 μg IgG control or CBP antibody (Abcam; ab46540 and ab2832, respectively) blocked with 1 μg fish sperm DNA. PCR was performed using primers (Supplementary Table S1) covering gene regulatory regions for CDC25A (2172 to 1870 relative to transcriptional start site, TSS), SKP2 (1772 to 1870 relative to TSS), and CDC25A (31 to 310 relative to TSS).

Gene expression microarray and data analysis

RNA was extracted from three biologic replicates of AsPC-1 cells 6 and 24 hours after treatment with 10 μmol/L ICG-001 or vehicle control (DMSO) or in separate experiments from two biologic replicates of AsPC1 cells transfected for 48 hours with either 20 nmol/L control or CTNNB1 siRNA. Affymetrix U133 plus 2.0 oligonucleotide arrays were processed in the UCLA Clinical Microarray Core. Arrays are available in Gene Expression Omnibus database repository (accession code GSE57728). Data analysis was performed with dChip Analysis software package (31) using invariant set normalization and signal intensities summarized using the model-based expression index algorithm with mismatch probe option for background subtraction. Initial gene filtering criteria were set as >10% present call and variance across samples of 0.4 < standard deviation/mean < 1.000. ICG-001-regulated genes were determined by comparative analysis of ICG-001 versus vehicle control (selection criteria >1.67-fold change and P < 0.01 at 6 hours or >2-fold change and P < 0.01 at 24 hours). β-catenin-regulated genes were determined by comparative analysis of CTNNB1 versus control siRNA transfection (selection criteria ≥1.33-fold change and ≥50 absolute change). Functional enrichment was examined using default parameters in the web-based Database for Annotation, Visualization and Integrated Discovery (DAVID, v6.7; http://david.abcc.ncifcrf.gov; ref. 32). Analysis was limited to the gene ontology (GO) biologic process FAT (GOTERM_BP_FAT) category terms and ranked on P values after removal of categories with less than 6 annotated genes.

Statistical analysis

Student t tests were used to compare continuous variables. The Cox proportional hazard model was used to estimate HRs between treatment groups. The assumption of proportionality was assessed both by visual inspection of Kaplan–Meier survival curves and formal analysis of Schoenfeld residuals (P = 0.13). Kaplan–Meier survival curves and log-rank tests were performed using GraphPad Prism.

Results

ICG-001 inhibits in vitro PDAC cell line growth

ICG-001 (Fig. 1A) effects on in vitro anchorage-dependent PDAC cell growth were addressed by MTT cell viability assays. ICG-001 showed dose-dependent cell growth inhibition of AsPC-1, L3.6pl, PANC-1, and MiaPaCa-2 cell lines at IC50 values of 5.48 μmol/L, 14.07 μmol/L, 3.43 μmol/L, and 3.31 μmol/L, respectively (Fig. 1B and Supplementary Fig. S1A and S1B). ICG-001 also significantly inhibited anchorage-independent growth in soft agar assays (Fig. 1C). Addressing the potential for combined use of ICG-001 with cytotoxic chemotherapy, concurrent treatment with 5 μmol/L ICG-001 and 5 nmol/L gemcitabine further increased growth inhibition relative to individual treatments (Fig. 1D).

ICG-001 inhibits in vivo PDAC tumor growth

ICG-001 was next addressed in an in vivo orthotopic xenograft model of PDAC. AsPC-1 tumor cells were injected into the distal pancreas of nude mice 10 days before the start of treatment. Tumor-bearing mice were then randomized into four different treatment arms, including vehicle (N = 12), ICG-001 (N = 12), gemcitabine (N = 11), or ICG-001 + gemcitabine (N = 12). Treatment was continued for a total of 8 weeks, after which all surviving animals were followed until the end of the study (120 days). ICG-001 significantly improved survival compared with vehicle alone as determined by Cox proportional hazard analysis [HR, 0.207; 95% confidence interval (CI), 0.079–0.543; P = 0.001]. Gemcitabine also significantly improved survival compared with vehicle (HR, 0.123; 95% CI, 0.045–0.334; P < 0.001). There was no survival difference between gemcitabine alone versus ICG-001 alone (HR, 0.592; 95% CI, 0.250–1.399; P = 0.23). In line with in vitro results, the greatest survival benefit relative to vehicle was seen with combined gemcitabine + ICG-001 (HR, 0.074; 95% CI, 0.026–0.212; P < 0.001). Although this combination improved survival relative to ICG-001 alone (HR, 0.360; 95% CI, 0.152–0.848; P = 0.02), there was no significant improvement relative to gemcitabine alone (HR, 0.608; 95% CI, 0.254–1.455; P = 0.66). Kaplan–Meier survival curves (Fig. 2A) also demonstrated improved survival relative to vehicle control (mean survival, 46 ± 3.1 days) for ICG-001 (mean survival, 64 ± 7.1 days, log-rank P = 0.01), gemcitabine (mean survival, 83 ± 5.1 days,
Figure 1. ICG-001 inhibits in vitro anchorage-dependent and -independent growth of pancreatic cancer lines. A, chemical structure of ICG-001. MTT cell viability (B) and soft agar assays (C) were performed at the indicated concentrations of ICG-001. D, MTT assay on AsPC-1 cells treated for 6 days with vehicle (V), 5 μmol/L ICG-001 (I), 5 nmol/L gemcitabine (G), or 5 μmol/L ICG-001 plus 5 nmol/L gemcitabine (I + G). Representative experiment from at least three replicates is presented for each cell line. *, P < 0.05; **, P < 0.01; ***, P < 0.001; and ns, not significant.
ICG-001 Inhibits Pancreatic Cancer Growth

log-rank $P < 0.00001$), and combined ICG-001 + gemcitabine (mean survival, 95 ± 6.0 days, log-rank $P < 0.00001$) treatments.

The in vivo biologic effects of ICG-001 were further addressed by gross and histologic analysis of mice at necropsy. All tumors significantly involved the pancreas

Figure 2. ICG-001 shows in vivo efficacy against pancreatic cancer. A, Kaplan-Meier survival curves for mice treated with vehicle (V), ICG-001 (I), gemcitabine (G), or ICG-001 plus gemcitabine (I + G). B, tumor dissemination scores were determined at the time of sacrifice for all mice in the four treatment arms. C, mitotic counts in 10 random high power fields and (D) qPCR analysis of indicated Wnt gene targets normalized to ACTB housekeeping gene were determined in primary tumors taken from mice still receiving treatment at time of death. E, weight of mice at various time points following initiation of therapy.

* $P < 0.05$; ***, $P < 0.001$; and ns, not significant.
with direct extension into adjacent spleen. Metastatic tumor deposits were observed in all animals, most frequently involving the lung, small bowel, and diaphragm (Supplementary Fig. S2A–S2F and Supplementary Table S2). Using a previously described scoring system that awards points based on tumor infiltration and metastasis (29), tumor dissemination was quantified at the time of death. No differences were observed between the four treatment arms (Fig. 2B), indicating that animals were reproducibly sacrificed at time points of equal tumor burden. A mitotic index calculated on tumors harvested during drug treatment revealed a significant decrease in mitotic activity in ICG-001 versus vehicle control–treated tumors (Fig. 2C). Real-time qPCR for three well-established Wnt target genes in tumors harvested during drug treatment revealed a significant decrease in MMP7 expression with ICG-001 versus vehicle control treatment, but no differences in BIRC5 or AXIN2 expression (Fig. 2D).

Pharmacologic inhibition of Wnt signaling could have potential deleterious effects on normal somatic stem cell maintenance and tissue homeostasis (26). However, no clinical evidence of ICG-001 cytotoxicity was observed on the basis of body weight measurements (Fig. 2E). Furthermore, H&E evaluation of uninvolved liver and intestine revealed no histologic changes to suggest cytotoxicity in animals sacrificed during treatment with ICG-001 or vehicle control. Small bowel from both treatment groups revealed normal villous:crypt ratios and no changes in apoptotic or mitotic activity within crypts, whereas liver showed no evidence of hepatitis, cholestasis, or hepato-cellular injury (i.e., ballooning change or apoptosis; Supplementary Fig. S2G–S2L).

**ICG-001 induces G1 arrest and has variable effects on Wnt/β-catenin signaling**

We next explored mechanisms underpinning ICG-001 pancreatic growth inhibitory effects. As previously shown in colorectal cancer (16), ICG-001 disrupted the interaction between CBP and β-catenin in AsPC1 cells as measured by coimmunoprecipitation (Fig. 3A). To examine ICG-001 effects on Wnt/β-catenin signaling, PDAC cell lines stably transduced with a β-catenin–activated luciferase reporter (7, 33) were treated with increasing concentrations of ICG-001. ICG-001 exhibited strong, dose-dependent inhibition of reporter activity in AsPC-1 (Fig. 3B), a cell line characterized by higher levels of autocrine Wnt/β-catenin activity (7). By comparison, high concentrations of ICG-001 only weakly inhibited reporter activity in PAN-1 and PANC-1.
MiaPaCa-2 cells, and not at all in L3.6pl cells (Fig. 3B). Parallel dose-dependent effects of ICG-001 on the expression of the endogenous Wnt/β-catenin target genes AXIN2 were also observed, with L3.6pl cells demonstrating disparate inhibition of AXIN2 expression at high ICG-001 concentration (Fig. 3C). Of note, ICG-001 significantly inhibited the growth of multiple PDAC cell lines at lower concentrations that had little or no effect on Wnt/β-catenin transcriptional activity (compare Fig. 1B and Fig. 3B and C).

ICG-001 has been shown to induce apoptosis via down-regulation of the apoptosis inhibitor BIRC5 (survivin), a known Wnt/β-catenin target gene (16–19). ICG-001 treatment decreased the expression of BIRC5 transcript and survivin protein levels in all four PDAC cell lines (Fig. 3D and E). Despite this significant inhibition of survivin expression, ICG-001 had no significant effects on AsPC1 apoptosis as determined by cleaved PARP, caspase-3, caspase-7, or Annexin-V–PI staining (Fig. 4A and B). PANC-1 and MiaPaCa-2 cells showed mild increases in cleaved PARP, caspase-3, and caspase-7 with no appreciable differences in apoptosis by Annexin-V–PI staining, whereas L3.6pl showed significantly increased apoptosis as measured by Annexin-V–PI flow staining (Fig. 4A and B). These modest changes indicated apoptosis was not the primary mechanism for the observed inhibition of PDAC growth by ICG-001. Therefore, ICG-001 effects on cell proliferation were analyzed by cell-cycle analysis. ICG-001 treatment robustly induced G₁ arrest in all PDAC cell lines (Fig. 4C), a finding consistent with the decreased mitotic activity observed in ICG-001-treated orthotopic tumors (Fig. 2C). Significant G₁ arrest was observed in all four cell lines at 10 μmol/L ICG-001, a concentration for which only AsPC-1 showed appreciable inhibition of Wnt transcriptional activity.

If ICG-001 exerts antiproliferative effects by inhibiting β-catenin-mediated transcription, this effect should be phenocopied by knockdown of β-catenin expression. However, siRNA-mediated CTNNB1 gene knockdown failed to induce G₁ arrest in AsPC-1 cells, whereas parallel ICG-001 treatment did induce significant G₁ arrest (Fig. 4D). Furthermore, although exogenous Wnt3A ligand treatment fully rescued ICG-001 inhibition of Wnt reporter activity in the cell lines, it had no effect on ICG-001–mediated G₁ cell-cycle arrest (Supplementary Fig. S3). Altogether, these data indicate that ICG-001 mediates growth arrest in PDAC cell lines through mechanisms discrete from its action as an inhibitor of Wnt signaling.

ICG-001 inhibits the expression of genes involved in cell cycle

To explore mechanisms underlying ICG-001 inhibition of cell cycle in PDAC, gene expression microarrays were performed on AsPC-1 cells after 6 and 24 hours of treatment with ICG-001. In total, 569 transcripts (419 upregulated and 150 downregulated) showed altered expression.
in response to ICG-001 treatment (P < 0.01; 1.67-fold change at 6 hours or 2-fold change at 24 hours; 0.2% median false discovery rate; Fig. 5A; and Supplementary Table S3). Several of these changes were further validated by qPCR in separate ICG-001 treatment experiments (Fig. 5B). To explore biologic processes linked to ICG-001 treatment, we performed enrichment analysis of GO functional annotations. In line with phenotypic observations, the top five GO terms for genes downregulated by ICG-001 were DNA replication, DNA metabolic processes, DNA replication initiation, DNA-dependent DNA replication, and cell cycle (P < 0.00013; Supplementary Fig. S4A). Top GO terms for genes upregulated by ICG-001 included multicellular organismal homeostasis, negative regulation of cell proliferation, cell-cycle arrest, regulation of angiogenesis, and regulation of cell proliferation (P < 0.001; Supplementary Fig. S4B).

Although its inhibition of PDAC cell proliferation did not seem mechanistically linked to its effects on Wnt/β-catenin transcriptional activity, ICG-001 did inhibit several known Wnt transcriptional targets, including MMP7 and LGR5 that were further validated by qPCR (Fig. 5B). To address ICG-001–regulated genes representing actual Wnt transcriptional targets in PDAC, we compared ICG-001 results with a second microarray study comparing gene expression changes in AsPC-1 transfected with either control or CTNNB1 siRNA. In the context of greater than 80% CTNNB1 knockdown, there were 441 altered transcripts (absolute fold change ≥1.33; median false discovery rate 10.4%), including 228 upregulated and 213 downregulated genes (Supplementary Table S3). Top GO terms for genes downregulated by CTNNB1 knockdown included cell fate commitment, tube morphogenesis, tube development, morphogenesis of a branching structure, and angiogenesis (P < 0.0005; Supplementary Fig. S5A). Top GO terms for genes upregulated by CTNNB1 siRNA included response to wounding, cell adhesion, biologic adhesion, response to inorganic substance, and regulation of cell migration (P < 0.0002; Supplementary Fig. S5B). Cross-referencing both ICG-001 and CTNNB1 siRNA microarray results revealed 117 overlapping transcripts (Fig. 5C; Supplementary Table S3). GO functional annotations were only marginally enriched in this overlapping dataset (P < 0.01), but included regulation of cell proliferation, positive regulation of developmental processes, homeostatic process, response to wounding, and regulation of the cell cycle.

Among the most highly regulated genes identified in the ICG-001 arrays were SKP2, CDC25A, and CDKN1A (p21), each regulators of cell-cycle progression. We
Therefore explored whether these genes were direct transcriptional targets of CBP that are altered in response to ICG-001 treatment. After 1-hour ICG-001 treatment, ChIP revealed reduced CBP occupancy at SKP2 and increased CBP occupancy at CDKN1A (Fig. 6A), corresponding, respectively, to aforementioned decreased SKP2 and increased CDKN1A gene expression results (Fig. 5). No change in CBP occupancy was observed at CDC25A (Fig. 6A), suggesting that it is transcriptionally downregulated indirectly in response to ICG-001. Further detailed time-course analyses of gene and protein expression revealed SKP2 transcript levels were reduced within 4 hours, whereas CDKN1A transcript levels were increased within 2 hours of ICG-001 treatment (Fig. 6B and C). Corresponding decrease in SKP2 protein expression and increase in p21 protein expression were observed within 4 to 6 hours of ICG-001 treatment (Fig. 6D). MYC protein levels were also decreased after 6 hours, although MYC transcript levels were unchanged (Fig. 6D and E), indicating that a posttranscriptional mechanism controls MYC protein levels following ICG-001 treatment.

Discussion

At least subsets of PDAC are dependent upon Wnt/β-catenin signaling for initiation and/or progression (6–10, 34), warranting exploration of ICG-001 and other Wnt inhibitors as potential therapeutics. PRI-724, an ICG-001 derivative, is presently under investigation in combination with gemcitabine in a phase I clinical trial for patients with metastatic pancreatic cancer (NCT01764477). We have demonstrated that ICG-001 significantly inhibits in vitro PDAC growth through induction of G1 cell-cycle arrest and improves survival in an in vivo orthotopic xenograft model of PDAC. Despite augmented PDAC growth inhibition in vitro, combined ICG-001 and gemcitabine did not further improve survival over gemcitabine alone in the xenograft model. It is possible that robust induction of G1 arrest with ICG-001 compromises the action of cytotoxic chemotherapy such as gemcitabine, which primarily kills cancer cells undergoing DNA synthesis in S phase. An analogous situation has been observed with CDK4 inhibitors that by inducing G1 arrest can reduce the efficacy of cytotoxic chemotherapy in certain circumstances (35). Further optimization of the dosing and delivery of ICG-001 (or PRI-724) is needed to resolve whether ICG-001 can be used effectively in combination with gemcitabine. Intriguingly, ICG-001 reduced expression of RRM1 in AsPC-1 microarrays. RRM1 expression directly correlates with gemcitabine resistance (36) and worse overall survival in PDAC (37, 38). Furthermore, ICG-001 was shown to act synergistically with
conventional chemotherapy to prolong survival in NOD/SCID mice engrafted with primary acute lymphoblastic leukemia (22). Thus, optimized combinations of cytotoxic regimens with ICG-001 may still offer additional survival benefit in PDAC or other tumors.

ICG-001 treatment and β-catenin knockdown regulated an overlapping set of genes in AsPC-1, including known targets of canonical Wnt signaling (i.e., MMPT, EDN1, LGR5, RNF43, and PORCN). Originally identified in a small-molecule library screen of compounds that inhibited β-catenin/T-cell factor (TCF)–dependent reporter activity, ICG-001 inhibits Wnt transcriptional activity by binding to the N-terminal domain of CBP and preventing its interaction with β-catenin (16). This not only has the potential to disrupt CBP-dependent β-catenin–TCF transcription, but also may increase the pool of β-catenin available to interact with p300. Like CBP, p300 functions either as a transcriptional coactivator or corepressor in a context-dependent manner (26, 39, 40). Kahn and colleagues have proposed a model of CBP/p300 differential coactivator usage whereby TCF–β-catenin–CBP-mediated transcription drives a nondifferentiated proliferative state with ICG-001 inducing a switch to TCF–β-catenin–p300-mediated transcription favoring cellular differentiation (39, 41). In keeping with this model, ICG-001 strongly induced G1 cell-cycle arrest in PDAC cell lines and inhibited the expression of certain genes linked to pluripotency, including LGR5 that marks progenitor cells in intestinal crypts and DCLK1 which was recently shown to mark a unique tumor initiating cell population in PDAC (42).

ICG-001 also regulated many genes unaltered by β-catenin knockdown, including several linked to DNA replication and cell-cycle regulation. Beyond β-catenin, ICG-001 could more generally alter gene expression by disrupting CBP interaction with any of a number of other known protein binding partners that includes many transcription factors (43). As an example, ICG-001 was recently shown to block CBP binding to γ-catenin, resulting in increased p300/γ-catenin interaction and decreased BIRC5 expression (22, 44).

ICG-001 can induce caspase-3/7–mediated apoptosis in colon cancer cells via downregulation of BIRC5 (16). Although ICG-001 treatment inhibited survivin protein levels, there were only variable and modest effects on apoptosis in PDAC cell lines. Rather, ICG-001 induced robust G1 cell-cycle arrest, which is perhaps not unexpected given CBP/p300 histone acetyltransferase activity is essential for cell proliferation and orderly G1–S transition (45). Several groups find that Wnt/β-catenin signaling promotes cellular proliferation in PDAC (4, 9) and while Wnt/β-catenin transcriptional targets MYC or CCND1 are commonly linked to its regulation of the cell cycle, transcript levels of these genes were not altered in PDAC cell lines in response to ICG-001 treatment. Moreover, growth inhibition and G1 cell-cycle arrest were observed in multiple PDAC cell lines at ICG-001 concentrations with little or no measurable effect on Wnt reporter activity or endogenous AXIN2 expression, indicating ICG-001 inhibition of PDAC cell proliferation was decoupled from its function as a Wnt inhibitor.

ICG-001 treatment altered the expression of numerous genes linked to DNA replication and cell cycle in AsPC-1 microarray analysis, both downregulating genes that promote (i.e., SKP2, CDC25A, CDC7, CCNE, and MCM2-MCM 6) and upregulating genes that inhibit (i.e., CDKN1A, CDKN1C, CDKN2B, MXD1, MXII, and BTG1) cell-cycle progression. ICG-001 induced rapid changes in CBP occupancy on SKP2 and CDKN1A regulatory regions with corresponding changes in mRNA and protein levels, implicating SKP2 and CDKN1A as direct targets of ICG-001–mediated cell-cycle arrest. SKP2 is a substrate component of the SCF E3 ubiquitin-protein ligase complex that promotes cell-cycle progression through ubiquitination and subsequent degradation of several proteins linked to cell-cycle inhibition, including p21, p27, p57, p130, and RASSF1A among others (46). ICG-001 increased CBP occupancy at CDKN1A promoter site in AsPC-1 cells, perhaps by increasing the availability of CBP to different subsets of transcription factors mediating CDKN1A expression. CDKN1A encodes the cyclin-dependent kinase inhibitor p21 that opposes the function of multiple cyclin–CDK complexes that mediate G1 and S cell-cycle progression. Increased p21 levels with ICG-001 could reflect decreased SKP2-mediated degradation of p21 and/or increased CDKN1A expression via CBP cotranscriptional activation. Although MYC transcript levels were unchanged, ICG-001 reduced MYC protein levels within 6 hours along with corresponding increases in several known targets of MYC-mediated transcriptional repression (i.e., CDKN1A, CDKN1C, and CDKN2B). It is intriguing to speculate how ICG-001 might indirectly antagonize MYC through additional posttranslational mechanisms linked to its protein stability or function. MXD1 and MXII, which were both upregulated in response to ICG-001 treatment, can inhibit the transcriptional activity of MYC by competing for its important heterodimerization partner MAX (47). CBP/p300-mediated acetylation has been shown to stabilize MYC protein and function (48), which could also be perturbed by ICG-001. Finally, ICG-001 could indirectly disrupt MYC activity through its aforementioned downregulation of SKP2, which has been shown to ubiquitylate MYC to license its function as a transcriptional activator (49).

In conclusion, ICG-001 seems to robustly inhibit PDAC growth through both direct and indirect mechanisms that mutually reinforce the induction of G1 cell-cycle arrest. Although further studies are needed to expand upon precise mechanisms underpinning its transcriptional and phenotypic activities, ICG-001 seems to more broadly disrupt CBP function beyond its effects as cotranscriptional activator of Wnt/β-catenin signaling. These future studies should not only further examine the therapeutic potential of ICG-001 and its derivatives in PDAC or other cancers, but also better establish effective drug combinations and patient selection.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions

References

Grant Support
M.D. Arensman was supported by USHHS Ruth L. Kirschenstein Institutional National Research Service Award #T32 CA009056 (UCR Tumor Biology Training Grant). D.W. Dawson was supported by an American Cancer Society Research Scholars Grant (RSG-12-083-01-BKC), NIH (P50 CA163200), and the Hirshberg Foundation for Pancreatic Cancer Research. Flow cytometry was performed in the UCLA Jonsson Comprehensive Cancer Center (JCCC) and Center for AIDS Research Flow Cytometry Core Facility supported by NIH awards CA-16042 and AI-28697, and by the JCCC, UCLA AIDS Institute, and David Geffen School of Medicine at UCLA.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 22, 2013; revised July 9, 2014; accepted July 12, 2014; published OnlineFirst July 31, 2014.
Molecular Cancer Therapeutics

The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth


[Updated version](http://mct.aacrjournals.org/content/suppl/2014/08/01/1535-7163.MCT-13-1005.DC1)

[Supplementary Material](http://mct.aacrjournals.org/content/13/10/2303.full#related-urls)

This article cites 48 articles, 15 of which you can access for free at:
[http://mct.aacrjournals.org/content/13/10/2303.full#ref-list-1](http://mct.aacrjournals.org/content/13/10/2303.full#ref-list-1)

This article has been cited by 1 HighWire-hosted articles. Access the articles at:
[http://mct.aacrjournals.org/content/13/10/2303.full#related-urls](http://mct.aacrjournals.org/content/13/10/2303.full#related-urls)

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.